Overview

A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.
Phase:
Phase 1
Details
Lead Sponsor:
Epizyme, Inc.
Treatments:
Itraconazole
Rifampin